Loading
IRAK1 (Interleukin-1 receptor-associated kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Multiple myeloma.
Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signalling pathways. Is rapidly recruited by MYD88 to the receptor-signalling complex upon TLR activation.
Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, somatic mutation 0.61, clinical 0.91). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Plasma Cell Myeloma. In OnCo, 1 product record names it (Pacritinib).
In plain words · IRAK1 (Interleukin-1 receptor-associated kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Multiple myeloma.
IRAK1 (Interleukin-1 receptor-associated kinase 1) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Multiple myeloma.
Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signalling pathways.
No product in this corpus aims at IRAK1 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 1 medicine aimed at it (Pacritinib) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA IRAK1: RNA low tissue specificity; high antibody staining in 10 normal tissues; highest cancer staining carcinoid (1 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms, Multiple myeloma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas IRAK1 tissue; Open Targets ENSG00000184216 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Cao et al, Science, 1996, "IRAK: a kinase associated with the interleukin-1 receptor". Source.
Sources: HGNC HGNC:6112 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P51617 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000184216 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: myeloproliferative neoplasm 0.58 (GraphQL API, CC0)); IntOGen IRAK1 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signalling pathways. Is rapidly recruited by MYD88 to the receptor-signalling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. Location: Cytoplasm; Nucleus; Lipid droplet (UniProt). Locus Xq28 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Appendix, Bone marrow, Bronchus, Caudate, Cervix, Duodenum, Endometrium.
Medium only: breast cancer, colorectal cancer, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IRAK1" OR ABSTRACT:"IRAK1" OR TITLE:"interleukin 1 receptor associated kinase 1" OR ABSTRACT:"interleukin 1 receptor associated kinase 1" OR TITLE:"Interleukin-1 receptor-associated kinase 1" OR ABSTRACT:"Interleukin-1 receptor-associated kinase 1" OR TITLE:"pelle" OR ABSTRACT:"pelle") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IRAK1, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), IntOGen, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), IntOGen, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), IntOGen, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), IntOGen, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), IntOGen, Open Targets Platform.